The answer so far

One small human study measured the body’s own MOTS-c during exercise; separate experiments gave the peptide to mice. Those observations do not establish that a MOTS-c product improves human fitness, energy or longevity.1

On this page
  1. Where did the exercise idea come from?
  2. What happened in mice?
  3. Why is a signal not an exercise replacement?
  4. Can the MOTS-c trial listing be verified?
  5. How does this compare with SS-31?
  6. Sources
LINKED BUILDING BLOCKSAmino acids joined into a chainSequence and structure both matter
Conceptual schematic. Simplified and not to scale; not a scan, microscopy image or validated simulation.

Where did the exercise idea come from?

In 2021 researchers asked whether exercise changes the body’s own MOTS-c. They collected blood and muscle samples from ten sedentary healthy young men around a stationary-cycle session. Measured levels rose in muscle after exercise and in blood during and after exercise; the blood measurement returned toward baseline after rest. It was a small observation of a specific group and exercise session—not a trial of a product.1

One paper, different questionsAn evidence map, not a comparison of human product effects.
  • People exercisedTen healthy young men had their own MOTS-c measured; they were not given the peptide.
  • Mice received MOTS-cSeparate animal experiments measured performance in several physical tests.
  • An unverified listingA MOTS-c registry entry cannot be relied on as proof of an operating trial; see the explanation below.
  • The unanswered questionWhether a defined product improves meaningful outcomes or is safe in people.

What happened in mice?

The same paper separately gave MOTS-c to mice and reported better performance on some tests, including treadmill and coordination measures. A measured improvement on a mouse test is interesting, but it does not reveal whether people will feel more energetic, improve fitness or live longer. Different species, product exposure and outcomes all matter. Two authors disclosed consulting and shareholding interests in a biotechnology company.1

Why is a signal not an exercise replacement?

Exercise changes many systems at once, including muscles, circulation and the nervous system. A substance that responds to exercise might be one part of that biology; measuring it does not establish that giving it to a person recreates the whole response. Equally, not having a proven product does not make the underlying research uninteresting. Explore the broader questions about muscle and exercise.1

Can the MOTS-c trial listing be verified?

ClinicalTrials.gov contains a Hudson Biotech record describing a MOTS-c study in people with prediabetes. We cannot verify that it is operating: two other entries with the same sponsor and site explicitly call themselves fictional or mock. The MOTS-c entry does not itself say this, so that association does not prove it is fictional. We previously described it as a planned trial, which was too certain. Treat the record as unverified, not evidence that recruitment or results exist. For a different, completed study of a related molecule, compare CB4211 with MOTS-c.256

How does this compare with SS-31?

MOTS-c and elamipretide (SS-31) are different peptides. Elamipretide has been studied in people and has a specific US approval for Barth syndrome; those findings cannot be transferred to MOTS-c or assumed to validate a stack. Follow the elamipretide studies, or return to the MOTS-c overview for safety and policy context.43

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisNature Communications / PubMed Central · Primary human observation and mouse experimentsAccess checked 2026-11-05 · Source date: 2021-01-20 · Ten healthy sedentary young men measured around exercise; mice received MOTS-c. Two authors disclosed consulting and shareholding in CohBar. No human MOTS-c product administered in the observational portion.
  2. Study of MOTS-c in adults with prediabetes and overweight or obesity (NCT07505745)ClinicalTrials.gov / US National Library of Medicine · Sponsor-submitted registry listing; operation unverifiedAccess checked 2026-11-05 · Record lists Hudson Biotech and the same site as other records explicitly labelled fictional or mock; this entry does not label itself that way. No independent confirmation of operation; no results posted when checked.
  3. July 2026 Pharmacy Compounding Advisory Committee: MOTS-c presentationU.S. Food and Drug Administration · Regulator advisory committee briefing presentationAccess checked 2026-11-05 · Source date: 2026-07 · MOTS-c section from PDF page 121. No identified clinical administration studies in agency review; describes uncertainties in characterisation, immunogenicity and safety.
  4. FDA Grants Accelerated Approval to First Treatment for Barth SyndromeU.S. Food and Drug Administration · US regulatory approval announcement, 2025Accessed 2026-11-05
  5. TB-500 cardiovascular biomarkers listing (NCT07487363)ClinicalTrials.gov / U.S. National Library of Medicine · Sponsor-submitted registry record explicitly described as fictionalAccess checked 2026-11-05 · Source date: 2026-03-23 · The sponsor-submitted summary calls this record fictional; same sponsor and site as two other peptide listings. That association alone does not establish whether either other listing is fictional.
  6. Tesamorelin liver-fat listing: mock study (NCT07481734)ClinicalTrials.gov / U.S. National Library of Medicine · Sponsor-submitted registry record explicitly titled mock studyAccess checked 2026-11-05 · Source date: 2026-03-19 · Sponsor-submitted title calls this a mock study; same sponsor and site as two other peptide listings. It does not establish whether either other listing is fictional.